Key result
GRT-R910 was well-tolerated with mostly mild to moderate transient adverse events and no treatment-related serious adverse events, while boosting and maintaining neutralizing antibody titers for at least 6 months.
Why the study?
Humoral immunity induced by authorized SARS-CoV-2 vaccines wanes within 6 months, and frequent boosts may only offer transient protection, especially in older adults facing severe complications.
Does the GRT-R910 self-amplifying mRNA vaccine safely boost immunity in previously vaccinated healthy older adults?
Does the GRT-R910 self-amplifying mRNA vaccine safely boost immunity in previously vaccinated healthy older adults?
The self-amplifying mRNA vaccine GRT-R910 is safe and induces durable neutralizing antibody and T cell responses for at least 6 months in previously vaccinated older adults.
Answers are grounded in this paper and cite their sources.
May support durable samRNA boosting in older adults; leaves open confirmation of clinical protection in larger trials.
SARS-CoV-2 has resulted in high levels of morbidity and mortality world-wide, and severe complications can occur in older populations. Humoral immunity induced by authorized vaccines wanes within 6 months, and frequent boosts may only offer transient protection. GRT-R910 is an investigational self-amplifying mRNA (samRNA)-based SARS-CoV-2 vaccine delivering full-length Spike and selected conserved non-Spike T cell epitopes. This study reports interim analyses for a phase I open-label dose-escalation trial evaluating GRT-R910 in previously vaccinated healthy older adults (NCT05148962). Primary endpoints of safety and tolerability were assessed. Most solicited local and systemic adverse events (AEs) following GRT-R910 dosing were mild to moderate and transient, and no treatment-related serious AEs were observed. The secondary endpoint of immunogenicity was assessed via IgG binding assays, neutralization assays, interferon-gamma ELISpot, and intracellular cytokine staining. Neutralizing antibody titers against ancestral Spike and variants of concern were boosted or induced by GRT-R910 and, contrasting to authorized vaccines, persisted through at least 6 months after the booster dose. GRT-R910 increased and/or broadened functional Spike-specific T cell responses and primed functional T cell responses to conserved non-Spike epitopes. This study is limited due to small sample size, and additional data from ongoing studies will be required to corroborate these interim findings.
No takes yet. Share an insight, caveat, or question.
Palmer et al. (2023) studied SARS-CoV-2 vaccination (n=17). GRT-R910 was evaluated on Safety and tolerability. GRT-R910 was well-tolerated with mostly mild to moderate transient adverse events and no treatment-related serious adverse events, while boosting and maintaining neutralizing antibody titers for at least 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: